- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about VRTX
Recent news which mentions VRTX
Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients
February 06, 2024
From Benzinga
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
February 06, 2024
Tickers
VRTX
From Motley Fool
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
February 06, 2024
From Benzinga
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
February 06, 2024
From InvestorPlace
This High-Flying Stock Just Got Some Bad News: Should You Sell?
February 06, 2024
Tickers
VRTX
From Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
February 05, 2024
Tickers
VRTX
From Motley Fool
Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday?
February 05, 2024
From Benzinga
Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
February 05, 2024
From Benzinga
Will Jerome Powell Spoil Wall Street's Party? US Stock Futures Slip As Fed Chief Maintains Hawkish Tone Ahead Of More Earnings
February 05, 2024
From Benzinga
Earnings Scheduled For February 5, 2024
February 05, 2024
From Benzinga
Investor Optimism Improves Following Tech Earnings, Jobs Data; S&P 500 Gains For 4th Week
February 05, 2024
From Benzinga
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
February 02, 2024
Tickers
VRTX
From Motley Fool
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
February 01, 2024
From InvestorPlace
Buy Alert: 3 Stocks Sitting in the Sweet Spot
January 31, 2024
From InvestorPlace
Key Takeaways From Vertex Pharmaceuticals Analyst Ratings
January 31, 2024
Tickers
VRTX
From Benzinga
Why Vertex Pharmaceuticals Stock Topped the Market Today
January 30, 2024
Tickers
VRTX
From Motley Fool
Why Is Vertex Pharmaceuticals Stock Sliding Today?
January 30, 2024
From Benzinga
Is CRISPR Therapeutics a Buy in the New Bull Market?
January 30, 2024
From Motley Fool
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
January 29, 2024
From Benzinga
3 Magnificent Stocks to Buy and Hold Forever
January 27, 2024
From Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
January 25, 2024
From Motley Fool
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
January 25, 2024
From InvestorPlace
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
From Benzinga
Where Will CRISPR Therapeutics Be in 5 Years?
January 24, 2024
From Motley Fool
From Benzinga
2 Super Stocks You'll Wish 5 Years From Now That You'd Bought Today
January 24, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.